Antidepressants Market Size & Share, by Drug Class (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclic, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors); Indication (Major Depressive Disorder, Anxiety Disorder, Panic Disorder) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4469
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Antidepressants Landscape

top-features-companies
    • AbbVie Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Alkermes
    • Sun Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Pfizer Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca PLC
    • GlaxoSmithKline plc
    • Bristol-Myers Squibb Company 

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • AbbVie Inc., submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) to the U.S. Food and Drug Administration (FDA) to treat major depressive disorder (MDD) in patients receiving existing antidepressants.

  • Alkermes, announced the receiving of Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD).


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4469
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Worldwide surge in mental disorders, significant rise in stress level, increasing approval for novel antidepressants are some major factors driving the growth of the market.

The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2033.

High expenditure for developing antidepressants, side effects associated with antidepressants, and stringent government regulations are estimated to hamper the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are AbbVie Inc., Alkermes, Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, indication, and by region.

The selective serotonin reuptake inhibitors segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying